Free Trial

Benitec Biopharma Q2 2024 Earnings Report

Benitec Biopharma logo
$11.30 -0.27 (-2.33%)
As of 02/21/2025 04:00 PM Eastern

Benitec Biopharma EPS Results

Actual EPS
-$2.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Benitec Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Benitec Biopharma Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Benitec Biopharma Earnings Headlines

Benitec Biopharma reports Q2 EPS (33c) vs ($2.64) last year
Buy NVDA Now?
After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chipmaker has struggled this year, facing increased competition and regulatory pressure.
See More Benitec Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email.

About Benitec Biopharma

Benitec Biopharma (NASDAQ:BNTC), a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

View Benitec Biopharma Profile

More Earnings Resources from MarketBeat